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Background. The potential medical applications of nanomaterials are shaping the landscape of the nanobiotechnology field and
driving it forward. A key factor in determining the suitability of these nanomaterials must be how they interface with biological
systems. Single walled carbon nanotubes (CNT) are being investigated as platforms for the delivery of biological, radiological, and
chemical payloads to target tissues. CNT are mechanically robust graphene cylinders comprised of sp
2-bonded carbon atoms and
possessing highly regular structures with defined periodicity. CNT exhibit unique mechanochemical properties that can be
exploited for the development of novel drug delivery platforms. In order to evaluate the potential usefulness of this CNT scaffold,
we undertook an imaging study to determine the tissue biodistribution and pharmacokinetics of prototypical DOTA-
functionalizedCNT labeled withyttrium-86 and indium-111 (
86Y-CNT and
111In-CNT, respectively) in a mouse model. Methodology
and Principal Findings. The
86Y-CNT construct was synthesized from amine-functionalized, water-soluble CNT by covalently
attaching multiple copies of DOTA chelates and then radiolabeling with the positron-emitting metal-ion, yttrium-86. A gamma-
emitting
111In-CNT construct was similarly prepared and purified. The constructs were characterized spectroscopically,
microscopically, and chromatographically. The whole-body distribution and clearance of yttrium-86 was characterized at 3 and
24 hours post-injection using positron emission tomography (PET). The yttrium-86 cleared the blood within 3 hours and
distributed predominantly to the kidneys, liver, spleen and bone. Although the activity that accumulated in the kidney cleared
with time, the whole-body clearance was slow. Differential uptake in these target tissues was observed following intraveneous or
intraperitoneal injection. Conclusions. The whole-body PET images indicated that the major sites of accumulation of activity
resulting from the administration of
86Y-CNT were the kidney, liver, spleen, and to a much less extent the bone. Blood clearance
was rapid and could be beneficial in the use of short-lived radionuclides in diagnostic applications.
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INTRODUCTION
How nanomaterials interface with biological systems is a key
question that may impact the emerging field of nanomedicine.
The pharmacokinetic profile of these unique, new materials is
a prominent factor in determining their suitability for in vivo
applications. The important issues of where they distribute in vivo
and how they clear from a living system must be addressed. Single
walled carbon nanotubes [1] (CNT) are promising scaffolds for
transporting biological cargo across cellular membranes [2–5]. A
report [6] of the murine biodistribution of an
125I-labeled
hydroxylated-CNT into the stomach, kidney, and bone was
contrasted by another report [7] describing the rapid blood and
whole body clearance of an
111In-labeled diethylenetriaminepen-
taacetic acid (DTPA) derivatized-CNT from mice. The pharma-
cokinetics of an unmodified-CNT suspended in surfactant was also
reported [8] in rabbits utilizing the inherent CNT near-infrared
fluorescence for detection and demonstrated rapid blood clearance
and only liver accumulation. We attached 1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10-tetraacetic acid (DOTA), a radiometal chela-
te moiety, to soluble, amino-functionalized-CNT [9,10] and
radiolabeled with the short half-lived, positron-emitting
86Y
(t1/2=14.7 h) or the long half-lived, gamma-emitting
111In
(t1/2=2.81 d). The goal of this study was to map the in vivo
distribution of our soluble prototype CNT scaffold in real time and
evaluate the pharmacokinetic profile using PET and conventional
tissue harvest techniques. Herein, we report the PET imaging and
biodistribution of a positron-emitting CNT construct in mice. PET
was chosen because it provides extremely sensitive, quantitative,
and functional information that is different from that obtainable
with other largely anatomical imaging modalities and CT was
performed to confirm anatomical assignments [11].
METHODS
Synthesis and Characterization of
86Y-CNT
Pristine single walled carbon nanotubes (CNT) were shortened
and purified by oxidative acid digestion. Briefly, 60 mg of CNT
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# 1280YJ) were refluxed in 2M HNO3 (60 mL) for 48 hours. In
addition, sonication was performed at 70uC with 100 watts for
0.5 h with a Biologics Model 300 V/T Ultrasonic Homogenizer
(Manassas, VA) using the 3/8’’ diameter stepped titanium tip. The
CNT were again refluxed for an additional 10 h in the 2M HNO3.
This digestion and sonication yields purified and shortened
carboxy-functionalized CNT molecules (Figure 1, Compound 1).
Raman spectroscopy was employed to characterize 1 using
a Renishaw InVia microRaman system (Gloucestershire, United
Kingdom) equipped with a 488 nm laser. Samples were
evaporated on silicon substrates.
The carboxy-functionalized CNT molecules were functiona-
lized and subsequently solublized by covalent attachment of
reactive sidewall amino groups [9,10] yielding CNT-(NH2)
(Figure 1, compound 2). Raman spectroscopy was employed to
characterize 2 (as described above) and the number of primary
amines that were appended per mass of CNT was measured using
the Sarin assay [12].
The water soluble CNT-amine construct, 2, was reacted with 2-
(p-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA-NCS, Macrocyclics, Inc., Dallas, TX) to
yield a CNT-DOTA construct in metal-free conditions at pH 9.5
(adjusted with 1 M metal free carbonate solution) for 40 minutes
at room temperature at a stoichiometry of 2:1 (DOTA-NCS to
amine). The product was purified using a 10 DG gel permeation
column (BioRad, Hercules, CA) with metal-free water (MFW,
Purelab Plus System, U.S. Filter Corp., Lowell, MA) as the mobile
phase. The 10 DG column was rendered metal free by washing
with 30 mL of 10 mM EDTA followed by rinsing with 60 mL of
MFW. The product was lyophilized to yield a solid that was the
CNT-DOTA construct (Figure 1, compound 3). Raman spectros-
copy was employed to characterize 3 (as described above). AFM
images were obtained using a Veeco Dimension 3100 (Woodbury,
NY) operated in the tapping mode with a scanning frequency of
84 Hz and a scan rate of 0.500 Hz. Cantilever tips were supplied
from Vecco probes (force constant of 3 k/m). Samples were spin
coated onto a freshly cleaved mica surface. TEM images were
obtained using a Philips EM-201 (Amsterdam, Netherlands) with
1 nm resolution, HV=80 kV. Samples are adsorbed onto plasma-
treated formvar-coated copper grids. Ultraviolet-visible (UV-Vis)
spectroscopic and chromatographic characterization of 3 was
performed by gel permeation HPLC using a Beckman Coulter
System Gold Bioessential 125/168 diode array detection system
(Beckman Coulter, Fullerton, CA) equipped with an in-line Jasco
FP-2020 fluorescence detector (Tokyo, Japan). Briefly, 0.020 mg
of 3 dissolved in N,N-dimethylformamide (DMF, Sigma Biotech
grade 99.9+%) was chromatographed with a stationary phase of
PLgel MIXED-A column (300 mm67.5 mm) (Polymer Labora-
tories, Amherst, MA) and a DMF mobile phase at 1 mL/min at
ambient temperature. The extent of DOTA substitution per mass
of CNT in compound 3 was determined using the spectrophoto-
metric method [13] of Dadachova et al. The number of primary
amines that remained after appending the DOTA-NCS was again
assayed using the Sarin assay [12]. The mass of CNT was
determined using UV-Vis spectroscopy (at 600 nm) to measure the
CNT concentration from the linear region of a standard curve of
absorbance at 600 nm versus different concentrations of CNT.
Yttrium-86 was produced in the Memorial Sloan-Kettering
Cancer Center cyclotron core facility via the (p,n) nuclear reaction
on an enriched strontium-86 target, and chemically separated
from the target using ion chromatographic techniques [14,15].
Activity was assayed in a Squibb CRC-15R Radioisotope
Calibrator (E.R. Squibb and Sons, Inc., Princeton, NJ) set at
711 and dividing the displayed activity value by 2.
The
86Y-CNT construct (Figure 1, compound 4) was prepared
by adding 296 MBq (8 mCi) of acidic
86Y chloride to 0.150 mg of
CNT-DOTA (compound 3) (10 g/L) in MFW and 0.050 mL of
3 M ammonium acetate (Aldrich Chemical Co., Milwaukee, WI)
to yield a pH 5.5 solution. The reaction mixture was heated to
60uC for 30 min. and then purified by size exclusion chromatog-
raphy using a P6 resin (BioRad) as the stationary phase and 1%
human serum albumin (HSA, Swiss Red Cross, Bern, Switzerland)
in 0.9% NaCl (Abbott Laboratories, North Chicago, IL) as the
mobile phase.
The control construct was a mixture of
86Y-DOTA and CNT-
amine (compound 2). This mixture was prepared by the adding
37 MBq (1 mCi) of acidic
86Y chloride to 0.5 mg (10 g/L in
MFW) of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA, Macrocyclics, Inc.) and 0.050 mL of 3M ammonium
acetate to yield a pH 5.5 solution. The reaction mixture was
heated to 60uC for 30 min. and then purified by size exclusion
chromatography as described above. 0.150 mg of 2 in MFW was
added to the
86Y-DOTA product and mixed.
A small aliquot of each final product was used to determine the
radiochemical purity by ITLC-SG using silica gel impregnated
paper (Gelman Science Inc., Ann Arbor, MI). The paper strips
were developed using two different mobile phases. Mobile phase I
Figure 1. Synthetic scheme to prepare
86Y-CNT.
doi:10.1371/journal.pone.0000907.g001
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strips were spotted, developed, dried and counted intact using an
Ambis 4000 gas ionization detection system (Ambis Inc., San
Diego, CA).
Synthesis and Characterization of
111In-CNT
The analogous
111In-CNT construct (compound 5) was prepared
by adding 111 MBq (3 mCi) of acidic
111In chloride (Perkin
Elmer, N. Bellerica, MA) to 0.150 mg of 3 (10 g/L) in MFW and
0.050 mL of 3 M ammonium acetate to yield a pH 5.5 solution.
The reaction mixture was heated to 60uC for 30 min. and then
purified by size exclusion chromatography using a P6 resin as the
stationary phase and 1% HSA in 0.9% NaCl as the mobile phase.
A small aliquot of the final product was used to determine the
radiochemical purity by ITLC-SG using the methods described
above. Combined spectroscopic, radiographic, and chromatograph-
ic characterization of the CNT construct was performed by reverse
phase HPLC, using a Beckman Coulter System Bioessential 125/
168 diode array detection instrument equipped with an in-line c-
RAM Model 3 radioactivity detector (IN/US, Tampa, FL). There
was a delay of 0.3 min. that corresponded to the time to transit from
the diode array detector to the downstream radionuclide detector.
Compound 5 (0.010 mg) was analyzed using a Gemini (Phenom-
enex,Torrence,CA)5ureversephaseC18column(25064.6 mm) to
chromatograph these molecules with a 0 to 100% gradient of 0.1M
tetraethylammonium acetate (Aldrich), pH 6.5 and acetonitrile
(Aldrich) at a flow rate of 1 mL/min.
Experimental Design
Ten male athymic nude mice (Taconic, Germantown, NY), 10–
12 weeks old, were separated into three groups. Group I (n=4)
received an intravenous (i.v.) injection of 6.7 MBq (0.18 mCi) and
0.012 mg 4 in 0.20 mL via the retroorbital sinus. Group II (n=3)
received an intraperitoneal (i.p.) injection of 6.7 MBq and
0.012 mg 4 in 0.20 mL. Group III (n=3) received an intravenous
(i.v.) injection of 13.3 MBq (0.36 mCi)
86Y-DOTA+0.015 mg of 2
in 0.20 mL via the retroorbital sinus. All animals were imaged by
PET on day 1 at 3 hours post-injection; group I and II animals
were imaged by CT at this time as well, while still under anesthesia.
On day 2, 24 hours post-injection, Group I and II animals were
imaged by PET. For all in vivo experiments housing and care were in
accordancewith the Animal Welfare Act and the Guide for the Care
and Use of Laboratory Animals. The animal protocols were
approved by the Institutional Animal Care and Use Committee
(IACUC) at Memorial Sloan-Kettering Cancer Center.
CT Imaging
CT imaging was performed using the CT component of the X-
SPECT (Gamma Medica, Northridge, CA) a dedicated small-
animal SPECT-CT scanner for non-invasive, ultra-high-resolution
imaging in vivo of single-photon-emitting radiotracers and ultra-
high-resolution CT scans for anatomic registration. The imaging
times for the CT studies were 10 min. with a resolution of
<0.100 mm. These CT imaging studies require animals to be fully
anesthetized using isofluorane anesthesia.
Micro-PET Imaging
The microPET Focus
TM 120 (CTI Molecular Imaging, Inc.,
Knoxville, TN) is a dedicated small-animal scanner for imaging
PET radiotracers. An energy window of 350–750 keV, a co-
incidence timing window of 6 nsec, and an acquisition time of 10–
20 min. were used. The resulting list-mode data were sorted into
2D histograms by Fourier re-binning and transverse images
reconstructed by filtered back-projection into a 1286128695
matrix. The reconstructed spatial resolution is 2.6 mm full-width
half maximum (FWHM) at the center of the field of view. The
image data were corrected for non-uniformity of response of the
microPET
TM (i.e. were normalized), deadtime count losses,
physical decay to the time of injection, and the
86Y positron
branching ratio but no attenuation, scatter, or partial-volume
averaging correction was applied. An empirically determined
system calibration factor (i.e. mCi/mL/cps/voxel) for mice was
derived by imaging a mouse-size cylinder containing
18F uniformly
dispersed in water and used to convert voxel count rates to activity
concentrations. The resulting image data were then normalized to
the administered activity to determine by region-of-interest
analysis the percent of the injected dose per gram (%ID/g) of
tissue corrected for radioactive decay to the time of injection.
Data Analysis
AsiPRO VM 5.0 software (Concorde Microsystems, Knoxville,
TN) was used to perform image and region of interest (ROI)
analyses with the PET and CT datasets. For the ROI analyses,
a minimum of 3 regions per tissue per animal were collected and
the average %ID/g and standard deviation determined. The
average %ID/g tissue per animal was used to determine an
average %ID/g per tissue per group and the standard deviation
within the group values was calculated. Standards of each injected
formulation were counted to quantify the %ID/g. Unpaired two-
tailed t-tests were performed to assess temporal differences of tissue
activity. Prism software (Graphpad Software, Inc., San Diego, CA)
was used for statistical analyses and plotting data. TEM image
analysis was performed using ImageJ software (NIH, http://rsb.
info.nih.gov/ij/). AFM image analysis was carried-out using
Nanoscope II software from Digital Instruments.
Biodistribution Data
Animals were sacrificed at 24 h post-injection and the kidneys,
liver and spleens were harvested according to approved IACUC
institutional protocols. Tissue samples were weighed and counted
in a Packard Cobra c-counter (Packard Instrument Co., Inc.,
Meriden, CT) using a 315–435 KeV window. Standards of each
injected formulation were counted to determine the %ID/g.
Blood Clearance and Excretion of
111In-CNT
In another biodistribution study, 0.007 mg of 5 (specific activity
37 GBq/g (1Ci/g)) were injected i.v., via the retroorbital sinus, per
BALB/c mouse (female, 8–12 weeks old, Taconic Farms, NY) and
the mice were divided into 5 groups of n=3 per group. One group
of mice was sacrificed at each of the following time points 1, 24,
96, 216 and 360 hours and tissue samples including blood, brain,
lung, heart, adipose tissue, liver, kidney, spleen and femur were
harvested, weighed and counted using a Packard Cobra Gamma
counter using the 15–550 KeV window. The %ID/g was
determined by measuring the activity of an aliquot of each
construct injectate. Urine samples were collected from mice
1 hour post injection. Activity was detected and the urine samples
were analyzed using the ITLC method described above.
RESULTS
The synthesis, radiolabeling, and characterization of
the CNT constructs
Pristine CNT were purified and shortened by digestion in dilute
nitric acid and sonication. The product of this process, 1, was
carboxy-functionalized CNT. The Raman spectrum of this
PET of Y-86-CNT in Mice
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feature at 200 cm
21 yields a CNT diameter of 1.1 nm and further
confirmation of the product identity is provided by the 1340 cm
21
disorder band (D band) and the sharp 1556 and 1584 cm
21
tangential mode (G band) resonances [16,17]. These CNT
(compound 1) were functionalized and solubilized by the covalent
sidewall attachment of pendant primary amines to yield
compound 2. The Raman spectrum of 2 (Figure 2b) was
characterized by the loss of the RBM feature and a rising baseline
due to increasing luminescence resulting from the enhanced
dispersion of this product in solution [18]. The amine content of
the construct was quantified using the Sarin assay [12], which
yielded a value of 1.76 mmol amine/g CNT. Subsequently, these
amines were reacted with DOTA-NCS to yield the CNT-DOTA
construct (compound 3). Raman characterization of 3 (Figure 2c)
confirmed the enhanced solubility (,10 g/L) of this construct by
the rising baseline [18], which partially masks the D and G bands.
Transmission electron and atomic force microscopic images
(Figure 3) of 3 are presented to demonstrate the composition,
identity and purity of the DOTA-functionalized CNT product.
Figure 3a displays the results of an image analysis of the TEM data
of a sampling of 22 ‘unbundled’ 3 in Figure 3b. This data shows
that the mean6standard deviation CNT length distribution of 3
was 42617 nm (n=22). The AFM and TEM images of 3 in
Figures 3c and d, respectively, show bundles of 3 with varying
thickness (approximately 1–20 nm) and lengths and the absence of
carbonaceous or nanoparticulate contaminants. A gel permeation
HPLC chromatograph of 3 is shown in Figure 4 with a major
absorbance peak at 11.7 min and the corresponding UV-Vis
absorbance spectrum of that peak demonstrating the characteristic
CNT spectral feature. This gel permeation chromatograph further
demonstrates the purity of 3, notably by the absence of the later
eluting amorphous carbon and nanoparticulate species [19], which
are highly fluorescent species [18] and that were not detected using
the in-line fluorescence detector. The DOTA content of 3 was
determinedusingaleadarsenazoassay[13],whichyieldedavalueof
0.30 mmol DOTA/g CNT; in addition 3 still contained some
unreacted amines assayed to be 0.27 mmol amine/g CNT.
Construct 3 was labeled with ‘‘no carrier added’’
86Yc h l o r i d e
[14,15] and purified by size exclusion chromatography. The
radiochemical purity of compound 4 was determined to be 90%
by ITLC methods and had a specific activity of 555 GBq/g (15 Ci/
g). The control construct was a mixture of
86Y-DOTA+2.T h e
86Y-
DOTA was 95% radiochemicaly pure as determined by ITLC-SG.
An
111In-CNT construct (compound 5) was similarly prepared
and purified. This radiochemical analog was used in ancillary
animal experiments to measure blood clearance and excretion in
vivo over an extended period of time due to it’s longer half-life.
111In has been extensively utilized as a surrogate radionuclide for
yttrium chemistry in pre-clinical and clinical studies. Compound 5
also served to validate the ITLC-SG methods for determining
radiochemical purity. The
111In-CNT product was determined to
be 90% by the ITLC methods described above, similar to the
observed ITLC-SG purity of 4. A reverse phase HPLC analysis of
5 confirmed the co-elution of CNT and radioactivity (Figure 5).
The diode array detected a sharp absorbance peak at 12.7 minutes
(Figure 5b) that was attributed to the
111In-CNT product and
confirmed by the characteristic CNT spectral signature (Figure 5c).
The corresponding radioactivity trace (Figure 5a) revealed a sharp
peak at 13.0 minutes that contained 90% of the eluted
radioactivity activity and after correction for the delay between
detectors, was assigned to the
111In-CNT product. Two uniquely
different chromatographic methods were developed and yielded
the same result for the radiochemical purity - the reverse phase
HPLC method and the isocratic ITLC method. The reverse phase
HPLC data also correlated the radioactivity with the CNT, thus
validating the use of ITLC to rapidly and quantitatively determine
radiochemical purity and identity of these constructs.
The biodistribution of the radiolabeled construct
and the control construct
The ten mice were separated into three groups, each mouse in
groups I and II received 0.012 mg of 4 labeled with 6.7 MBq of
86Y, administered i.v. or i.p., respectively. Animals in group III
(control group) each received a physical mixture of 13.3 MBq of
86Y-DOTA and 0.015 mg of 2 via i.v. injection. We evaluated the
biodistribution of 4 in vivo by serial PET and then performed
anatomic imaging using a dedicated small-animal CT scanner.
Software fusion of the resulting PET and CT images was carried
out to combine the images. The imaging results were confirmed by
sacrificing the animals and harvesting, weighing, and counting the
activity in the organs.
PET images of animals in groups I and II at 3 hours post-
injection clearly demonstrated accumulation of activity in the
kidneys, spleen and liver (Figure 6). The kidney images showed
uptake primarily in the renal cortex, while the renal medulla was
devoid of activity. There was no blood-pool activity observed in
these images. In group I, the
86Y-CNT construct appeared to
avidly localize in the spleen and liver. In group II, spleen and liver
uptake was significantly lower and a diffuse activity was evident
from the i.p. cavity suggesting a relatively slow egress from the i.p.
compartment into the vascular compartment. After 24 hours there
was no significant difference in the accumulated activity in the
spleen and liver within each group compared to the 3 hour time-
point. Additionally, the kidneys of the animals in groups I and II
had begun to clear the constructs. These data indicate that the
clearance from the spleen and liver is slower than from the
kidneys. The radioactivity in the liver of the group I animals was
still significantly higher than the group II animals at both time-
points evaluated. As expected for a stably chelated metal-ion
species with a relatively small molecular weight, the control
mixture cleared completely from group III within 3 hours. The
imaged radioactivity was located primarily in the bladder (,1
%ID/g at 3 hours) and was consistent with urinary excretion of
small molecules (data not included).
Figure 2. Raman spectra measured with a 488 nm laser. (a) acid-
oxidized and purified CNT, compound 1; (b) sidewall amine-functiona-
lized CNT, compound 2; (c) DOTA-functionalized CNT, compound 3. The
spectra for 1 and 2 are plotted on the left axis (0-120,000), and 3 on the
right axis (0–450,000).
doi:10.1371/journal.pone.0000907.g002
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images in each of the group I and II animals to extract a decay-
corrected activity concentration in various organs. Data (Figure 7a)
are reported as the mean6standard deviation %ID/g. The
kidneys had 8.3060.92 and 8.5061.05; the liver had 17.863.95
and 7.5461.38; the spleen had 14.362.0 and 9.761.3; and the
bone (femur and spine) had 2.2660.14 and 1.4460.23 %ID/g at
3 hours post-injection in the group I and II animals, respectively.
At 24 hours post-injection, the kidneys had 5.9661.23 and
5.4260.85; the liver had 15.862.90 and 8.8365.17; the spleen had
13.260.60 and 7.5162.12; and the bone had 2.0260.36 and
1.5660.17 %ID/g in the group I and II animals, respectively. The
accumulated activity in the kidneys cleared significantly in group I
(P=0.023) and group II (P=0.017) over this 21-hour period.
However, statistical analysis showed that the activity accumulated in
the spleen, liver and bone was not clearing over this period of time.
Residual
86Y-CNT activity that was slowly exiting the i.p.
compartment yielded poorer image contrast in the group II mice.
Interestingly, the construct activity that did exit the i.p. cavity had
the same kidney uptake as the i.v. administered construct at both
timepoints, but very different liver and spleen accumulation. The
%ID/g activity in the livers of group II animals is 42% of that in
the group I animals at 3 hours post-injection, and 56% of that in
the group I animals at 24 hours post-injection. It appeared that the
equilibration process is slow and the liver activity increases with
time in the group II animals.
Biodistribution data (Figure 7b) obtained from tissue harvest at
24 hours was in good agreement with the ROI data. The spleen
showed the same differential accumulation as the liver as a function
of i.p. versus i.v. administration. Group III control animals showed
no organ-specific uptake of
86Y with only small amounts of activity
(0.1 to 1 %ID/g) in the kidney, liver and spleen. The post-mortem
biodistribution data and the 3-hour PET images showed this
control mixture rapidly cleared from the group III mice.
The whole-body PET images indicated that the major sites of
accumulation of activity resulting from the administration of
86Y-
Figure 3. Microscopic images of 3 provide data to evaluate the (a) size distribution of 22 individual DOTA-CNT obtained from (b)
a representative TEM image of solubilized 3 (scale bar=100 nm); (c) AFM image of the height (scale bar=0–60 nm) and (d) TEM image (scale
bar=100 nm) of representative DOTA-CNT bundles.
doi:10.1371/journal.pone.0000907.g003
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bone. The % ID/organ values for kidney, liver, and spleen,
24 hours post- i.v. injection, were 5.9661.20, 15.261.54, and
0.8260.04, respectively. The corresponding % ID/organ values
for kidney, liver, and spleen, 24 hours post- i.p. injection, were
5.4860.61, 4.4661.08, and 0.6060.09, respectively. Whole-body
activity was decreasing over this 24 hour period of time, as we
could account for only about 20% of the total i.v. administered
activity in the group I animals and about 11% of the total activity
in the group II animals. In another biodistribution experiment,
111In-CNT was injected into mice and ITLC analysis of urine
samples obtained 1 hour after injection was consistent with
111In-
CNT being excreted.
The clearance of radiometal-labeled CNT constructs from the
blood compartment is rapid. This was observed in this study (no
blood pool activity at 3 h) and quantitatively measured in another
biodistribution study using the longer half-lived
111In. Briefly,
compound 5 was injected into mice using the retroorbital sinus
route and venous blood samples were obtained 1, 20, 96, 216, and
360 hours after injection from groups of three animals per
timepoint. The data are shown in Figure 8. After 1 hour
2.7660.14 %ID/g was still in the blood and after 20 h only
0.4160.05 %ID/g was in circulation. The experiment was
continued for 15 d at which time no activity was found in
circulation. Additional
111In-CNT biodistribution data are
presented in a study of lymphoma tumor targeting with an
antibody-functionalized, radiolabeled carbon nanotube [20].
Tissue harvest indicated that the major sites of
111In accumulation
were the kidney, liver, spleen, and to a much less extent the bone,
similarly to the
86Y accumulation.
111In cleared the kidneys more
rapidly than the spleen and liver.
DISCUSSION
The interface of CNT with biological systems is a key issue that
can be addressed in part by determining the pharmacokinetic
profile of these unique materials. Where do functionalized-CNT
distribute in vivo following administration and how do they clear
are the questions that were posed in this study. Published reports
of the biodistribution of soluble, sidewall-functionalized, radiola-
beled CNT in murine models [6,7,20] were very different. The
first two biodistributions were based on tissue harvest and did not
contain an imaging component. Wang et al. [6] used
125I-CNT
(l,300 nm) where the CNT were hydroxyl-functionalized. They
reported the
125I cleared the blood and accumulated in the
Figure 4. Gel permeation HPLC chromatograph of compound 3
(0.020 mg) dissolved in DMF on a stationary phase of PLgel MIXED-A
column with DMF mobile phase at 1 mL/min at ambient tempera-
ture. (a) Chromatograph is shown with absorbance at 330 nm. (b) The
UV-VIS absorbance spectrum of the peak at 11.7 min.
doi:10.1371/journal.pone.0000907.g004
Figure 5. Reverse phase HPLC chromatograph of
111In-CNT,
compound 5 (0.010 mg); (a) Radionuclide trace of 5; (b) Correspond-
ing chromatograph with absorbance at 350 nm (n.b., there was
a 0.3 min delay between the detectors); (c) The UV-VIS absorbance
spectrum of the peak at 12.7 minutes in panel b.
doi:10.1371/journal.pone.0000907.g005
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for free
125I. Bone and kidney had accumulated activity that
persisted for up to 6 days. 80% of the activity cleared the animals
over an 11 day period. They did not report notably different tissue
accumulations when the construct was administered i.v. or i.p.
Singh et al. [7] used CNT (l,300–1000 nm) that were amine-
functionalized, modified with DTPA anhydride, and then labeled
with
111In. The
111In cleared the blood compartment rapidly (within
3 hours) and surprisingly there was no significant tissue uptake.
McDevitt et al. [20] reported the selective targeting of tumor in vivo
using tumor-specific antibodies that were covalently-appended to
asoluble,
111In-radiolabeledCNTconstructrelativetocontrolsofai)
non-targetingantibody-appendedCNT construct;ii)anon-targeting
CNT construct, and iii) antibody alone. Clearance of the non-
targeting, radiolabeled CNT construct from the blood compartment
was rapid. Tissue harvest indicated that the major sites of
111In
accumulation were the kidney, liver, spleen, and to a much less
extent the bone.
111In cleared the kidneys more rapidly than the
spleen and liver. Radioactive CNT was in the urine samples
collected from mice 1 hour post injection. The covalent attachment
of antibodies to the CNT scaffold dramatically altered the kidney
biodistribution and pharmacokinetics relative to the non-targeting,
radiolabeled CNT construct.
Small globular molecules (,25 kDa) are typically filtered by the
kidney but may also be reabsorbed subsequently in the tubule.
Large globular molecules usually bypass clearance through the
kidney, CNT may not behave similarly due to their large aspect
ratio, unlike globular proteins. Singh et al. [7] observed rapid and
complete renal clearance of their injected material, which is difficult
to explain given the 25 kDa cut-off of the glomerulus and the 0.1 to
1 mDa (approximate) weight range of the CNT materials.
Compound 3, the DOTA-CNT starting material, used to
prepare the radiolabeled constructs 4 and 5, was microscopically,
spectroscopically, and chromatographically characterized to
confirm the identity and purity of this reagent. These were
‘‘short’’ tubes with mean lengths of 42617 nm (n=22) resulting
from the acid digestion and sonication processing steps [21–23].
The AFM and TEM images of 3 show bundles of varying
thickness and lengths with no carbonaceous or particulate
contaminants. Gel permeation chromatography of 3 identified
a major absorbance peak that had the spectral signature of CNT
and which did not exhibit any carbonaceous or particulate
contaminants. Compounds 4 and 5 were characterized by
traditional radiochemical ITLC methods which were validated
using radio-HPLC methods. The radioactivity (
86Yo r
111In) was
clearly associated with the CNT, which is not surprising given the
stability of the DOTA-metal-ion complex and the thiourea linkage
[24] between the DOTA and the CNT. Chelates such as DTPA
anhydride were significantly less stable than DOTA or backbone-
modified DTPA moieties [25–27].
Compounds 4 and 5, that we report herein, were fully water-
soluble and were stable in the 1% human serum albumin (HSA)
injection vehicle and stable in biological fluids [20]. We were not
surprised that high molecular-weight, water-soluble compounds
that are CNT-based were accumulated in the liver and spleen and
also in the kidney. Previous work [6,20] also observed accumu-
lation of their CNT constructs in the kidneys. Hydrophilic
fullerenes were reported [28,29] to partition into liver and spleen,
but exhibit little-to-no accumulation in kidney, presumably
because of their smaller size and shape. It was surprising that
the constructs reported by Singh et al. clear the mouse entirely
within a few hours and do not accumulate anywhere.
A pharmacokinetic report [8] of unmodified CNT (l,300 nm)
suspended in a surfactant and injected i.v. into rabbits employed
the inherent near-infrared fluorescence of CNT for detection in
blood and tissue samples. They report a rapid blood clearance
(half-life of 1.0 h) and were only able to detect CNT in the liver,
but not in any other tissue sample examined (0.020 mg/kg was
administered). The materials that they examined were unmodified,
insoluble CNT and these may exhibit very different properties
than the modified, soluble CNT constructs used in this and the
other three studies [6,7,20]. Others have coated CNT with non-
covalently attached radiolabeled- and RGD-labeled surfactants
and administered (0.05 mg/kg) to mice [30]. This type of
construct is more similar to the unmodified CNT [8] in that the
CNT was dispersed in a detergent solute to facilitate solubilization.
Figure 6. Fused PET and CT images at 3 hours post-injection of
86Y-CNT, compound 4, showing a transverse (z-direction, images a and d),
a coronal (y-direction, images b and e), and a sagittal (x-direction, images c and f) slice of one representative animal from group I (i.v., a, b and
c) and one from group II (i.p., d, e and f).
doi:10.1371/journal.pone.0000907.g006
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robust, covalently assembled constructs reported herein and
elsewhere [6,7,20], since the radiolabel and the RGD were not
attached to the CNT. Unfortunately, they did not report [30] the
biodistribution of the radiolabeled surfactant alone, so that one
can compare its biodistribution to that of the construct nor of
a control construct (e.g., labeled with a non-specific control
peptide sequence). Thus the biodistribution can not be inferred
with certainty.
In this biodistribution study we performed an in vivo imaging
study of soluble, sidewall-functionalized, radiolabeled CNT
constructs in mice utilizing PET. By employing PET imaging
(and tissue harvest), we were able to measure accumulation and
clearance in groups of living animals over time by observing each
subject. The radioactivity from these compounds also accumulated
in bone and kidney, was cleared rapidly from the blood, and was
excreted in the urine. The spleen and liver accumulation, and the
differential clearance from the i.p. cavity, may result from
a different hydrophobicity of the hydroxylated [6] versus chelate/
amine functionalized CNT. While our CNT constructs were
processed similarly to those in reference 7, in that paper the
isotope completely cleared the blood and body rapidly.
We speculated that the CNT most likely cleared via i)
longitudinal filtration [31] through the renal glomeruli, which
has a pore size of approximately 30 nm diameter or ii) active
secretion into the tubular lumen. Accumulation of CNT in the
kidneys, in particular in the renal cortex region where filtration
occurs, was clearly shown in Figure 6a-c. The effect of molecular
shape, charge and size on kidney clearance has been investigated
using different macromolecular solutes [32,33]. The frictional ratio
of the molecule plays an important role as does the shape in
crossing the glomerular barrier. The negatively charged capillary
endothelium, anionic glomerular basement membrane, and the
anionic podocyte cell coating might provide a charge gradient that
facilitates transit of amine-functionalized CNT from the blood to
the urine [31]. Differences in CNT construct purity, chemistry,
charge, and flexibility could alter the biodistribution. The covalent
attachment of antibody molecules to the CNT dramatically altered
the kidney biodistribution and pharmacokinetics compared to
111In-CNT in tumor-bearing versus non-tumor-bearing mice [20].
PET/CT provides a comprehensive measure of in vivo behavior to
which the physicochemical properties of each construct can be
compared.
A comparison of the PET images obtained at 3 and 24 hours
demonstrated that the diffuse activity imaged in the i.p. cavity of
the group II animal persists over the 24 hour period of the
experiment and the liver activity was less than that in the group I
animals. This observation was interesting since large globular
proteins, for example IgG (,150 kDa), injected into the i.p. cavity
of a mouse redistributed rapidly and reached equilibrium in the
blood within 5 to 6 hours (data not shown). The mean
86Y-CNT
construct size was approximately 100 kDa, but obviously it did not
behave as a globular protein. The persistence of radioactivity in
the i.p. cavity seemed to minimize liver and spleen accumulation.
The mass amounts of CNT construct that were used per animal
in this study (0.6 mg/kg) were in the same range as those that were
employed in a study with radio-labeled, targeting-antibody CNT
constructs in mice [20]. The amount of activity accumulated in the
organs of these animals after 24 hours (The % ID/organ values for
kidney, liver, and spleen, post- i.v. injection, were 5.9661.20,
15.261.54, and 0.8260.04, respectively; the corresponding values
post- i.p. injection, were 5.4860.61, 4.4661.08, and 0.6060.09,
respectively.) does not pose a problem in translating these
constructs to other studies. Further, we have demonstrated that
appropriately designed targeting diagnostic agents based on a CNT
platform might further alter liver, kidney and spleen accumula-
tion/clearance [20]. The rapid blood clearance of these
nanomaterials could prove beneficial when using short half-lived
radionuclides in diagnostic applications, as prolonged persistence
of blood-pool activity following antibody-construct administration
obscures target imaging due to a low signal-to-background ratio.
The mechanism of excretion from the kidneys must also be further
examined to better understand the construct parameters that affect
clearance.
Conclusion
The whole-body PET images indicated that the major sites of
accumulation of radioactivity resulting from the administration of
soluble, sidewall-functionalized
86Y-CNT were the kidney, liver,
spleen, and to a much less extent the bone. PET data provides
extremely sensitive, quantitative, and functional information that is
Figure 7. Biodistribution data obtained from the PET imaging
experiment and from tissue harvest. (a) Plot of the 2-dimensional
ROI data for all group I and II animals at 3 and 24 hours. Three regions
per tissue per animal were collected and the average %ID/g and
standard deviation determined. The average %ID/g tissue per animal
was then used to determine an average %ID/g per tissue per group and
the standard deviation within the group values was also calculated. (b)
Plot of the 24 hour biodistribution data obtained from tissue harvest,
weighing and counting of organs from group I, II, and III mice.
doi:10.1371/journal.pone.0000907.g007
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imaging modalities and CT was performed to confirm anatomical
assignments. The presence of activity in the renal cortex where
glomerular filtration occurs was clearly shown in Figure 6 and
correlates with the radioactivity found in the urine. Furthermore,
the rapid blood clearance that was observed can be beneficial in
the use of short-lived radionuclides in diagnostic applications by
reducing the background activity compared to target tissue
activity. The mass amounts of soluble CNT construct that were
used per animal (0.6 mg/kg) were 30-fold higher than those
applied in a study with un-functionalized CNT [8] and point-out
the utility of functionalized-CNT which not only improves
solubility but acts as a scaffold that can bear many copies of an
appended moiety. The CNT compounds in this study were very
short-length and chemically and radiochemically pure. The
extensive physical and chemical characterization studies yielded
a clear description of the identity and purity of these CNT
compounds and proved useful in better understanding their
pharmacokinetic profile. Furthermore, the careful radiochemical
characterization and experimental controls better correlated the
observed pharmacokinetic results with the composition and
identity of the material injected.
We believe that the results described herein encourage further
study of CNT constructs in vivo. This soluble, sidewall-
functionalized CNT platform rapidly cleared the blood compart-
ment and exhibited some distribution to the expected clearance
sites. We have also demonstrated the utilization of an antibody-
modified-CNT construct in targeting human tumor in a murine
model [20]. The emerging field of nano-medicine will find
applications for many such CNT-based molecular constructs
based upon this synthetic and imaging approach.
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